HRP20150815T1 - Stabilna formulacija injektibilnog paracetamola spremna za uporabu - Google Patents

Stabilna formulacija injektibilnog paracetamola spremna za uporabu Download PDF

Info

Publication number
HRP20150815T1
HRP20150815T1 HRP20150815TT HRP20150815T HRP20150815T1 HR P20150815 T1 HRP20150815 T1 HR P20150815T1 HR P20150815T T HRP20150815T T HR P20150815TT HR P20150815 T HRP20150815 T HR P20150815T HR P20150815 T1 HRP20150815 T1 HR P20150815T1
Authority
HR
Croatia
Prior art keywords
use injectable
stable ready
paracetamol formulation
solution
injectable paracetamol
Prior art date
Application number
HRP20150815TT
Other languages
English (en)
Inventor
Ioulia Tseti
Original Assignee
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., Ioulia Tseti filed Critical Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Publication of HRP20150815T1 publication Critical patent/HRP20150815T1/hr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

1. Stabilna vodena otopina paracetamola za uporabu u IV infuziji sadrži 2-hidroksipropil-beta-ciklodekstrin kao tvar za stabilizaciju i otapanje pri čemu je molarni omjer paracetamola prema 2-hidroksipropil-beta-ciklodekstrinu 100:1 do 1:1, a vodena otopina sadrži 2 mg do 200 mg paracetamola po mL otopine, nadalje sadrži EDTA i monotioglicerol kao stabilizirajuće tvari, pri čemu je koncentracija EDTA 0.0015 mg do 1 mg po mL otopine i koncentracija monotioglicerola je 0.015 mg do 1 mg po mL otopine.
HRP20150815TT 2009-07-23 2015-07-27 Stabilna formulacija injektibilnog paracetamola spremna za uporabu HRP20150815T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09009569.6A EP2277546B1 (en) 2009-07-23 2009-07-23 Stable ready to use injectable paracetamol formulation

Publications (1)

Publication Number Publication Date
HRP20150815T1 true HRP20150815T1 (hr) 2015-09-11

Family

ID=41264251

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150815TT HRP20150815T1 (hr) 2009-07-23 2015-07-27 Stabilna formulacija injektibilnog paracetamola spremna za uporabu

Country Status (11)

Country Link
EP (1) EP2277546B1 (hr)
CY (1) CY1116746T1 (hr)
DK (1) DK2277546T3 (hr)
ES (1) ES2545484T3 (hr)
HK (1) HK1153400A1 (hr)
HR (1) HRP20150815T1 (hr)
HU (1) HUE027032T2 (hr)
PL (1) PL2277546T3 (hr)
PT (1) PT2277546E (hr)
SI (1) SI2277546T1 (hr)
SM (1) SMT201500192B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414557B1 (es) 2012-01-16 2014-06-10 Novocat Farma, S.A. Composición acuosa de paracetamol para inyección
ZA201300398B (en) * 2012-11-27 2013-09-25 Genfarma Laboratories S L Injectable liquid formulation of the combination of tramadol and paracetamol
CN110167543A (zh) * 2016-09-16 2019-08-23 锡德克斯药物公司 包含对乙酰氨基酚和磺烷基醚环糊精的制剂
GR1010637B (el) * 2023-01-13 2024-02-15 Ιουλια Κλεωνος Τσετη Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
HUP0402549A3 (en) * 2001-12-18 2006-01-30 Tseti Ioulia Parenteral composition of paracetamol
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
US20100004171A1 (en) * 2006-08-08 2010-01-07 Bazan Nicolas G Therapeutic Methods for Neuropathic Pain
US9399012B2 (en) * 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen

Also Published As

Publication number Publication date
HK1153400A1 (en) 2012-03-30
PT2277546E (pt) 2015-09-25
ES2545484T3 (es) 2015-09-11
DK2277546T3 (en) 2015-08-17
SMT201500192B (it) 2015-09-07
CY1116746T1 (el) 2017-03-15
EP2277546A1 (en) 2011-01-26
PL2277546T3 (pl) 2015-10-30
SI2277546T1 (sl) 2015-09-30
HUE027032T2 (en) 2016-08-29
EP2277546B1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
PH12019500517A1 (en) Long-acting formulations of insulins
HRP20150815T1 (hr) Stabilna formulacija injektibilnog paracetamola spremna za uporabu
AR053737A1 (es) Formulacion pediatrica de topiramato
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
BR112013022556A8 (pt) composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
AR092840A1 (es) Elaboracion de degarelix
BR112014026334A2 (pt) forma de dosagem de grande volume de infusão de gencitabina e conjunto
FR2950533B1 (fr) Formulation liquide, stable, prete a l'emploi de ketoprofene
RS54362B1 (en) Intravenous infusion of IBUPROFEN
BRPI0907203A2 (pt) Forma galênica para a administração de triptanos via transmucosa oral
FR2937867B1 (fr) Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
BRPI0811850A2 (pt) Composição concentrada de esmolol, composição pronta para uso, e, método de dosagem de um paciente com uma composição de esmolol.
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
TH151334A (th) สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody)
UA103955C2 (ru) Стойкая инъекционная фармацевтическая композиция ацеклофенака и способ ее получения
ECSP15000500A (es) Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal
IN2013MU03543A (hr)
TR200806301A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
UA86146U (ru) Способ получения веществ с потенциальными физиологическими свойствами 1,1'-(2''-бром-2''-хлорэтенил)-бис-(5-бромурацил)
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon